ICU Resource Use in Critically III Patients following Chimeric Antigen Receptor T-Cell Therapy
- PMID: 32530704
- PMCID: PMC7560798
- DOI: 10.1164/rccm.202002-0286LE
ICU Resource Use in Critically III Patients following Chimeric Antigen Receptor T-Cell Therapy
References
-
- Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. JULIET Investigators. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2019;380:45–56. - PubMed
-
- Nastoupil LJ, Jain MD, Spiegel JY, et al. Axicabtagene ciloleucel (Axi-cel) CD19 chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory large B-cell lymphoma: real world experience. Blood. 2018;132:91.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources